Related references
Note: Only part of the references are listed.Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia
Chiara Elena et al.
BLOOD (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Chronic Myelomonocytic Leukemia: Focus on Clinical Practice
Mrinal M. Patnaik et al.
MAYO CLINIC PROCEEDINGS (2016)
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults
Michael R. Savona et al.
BLOOD (2015)
Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia
Kristen Meldi et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
Rafael Bejar et al.
BLOOD (2014)
Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms
F. Traina et al.
LEUKEMIA (2014)
ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients
M. M. Patnaik et al.
LEUKEMIA (2014)
Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management
Sameer A. Parikh et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia
Esperanza Such et al.
BLOOD (2013)
Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups
Francesco Onida et al.
HAEMATOLOGICA (2013)
Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia
Raphael Itzykson et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial
Thorsten Braun et al.
BLOOD (2011)
Cytogenetic risk stratification in chronic myelomonocytic leukemia
Esperanza Such et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
A framework for variation discovery and genotyping using next-generation DNA sequencing data
Mark A. DePristo et al.
NATURE GENETICS (2011)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)
P. W. Wijermans et al.
LEUKEMIA RESEARCH (2008)
Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia
Ahmed Aribi et al.
CANCER (2007)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson et al.
BLOOD (2006)
Decitabine improves patient outcomes in myelodysplastic syndromes - Resuits of a Phase III randomized study
H Kantarjian et al.
CANCER (2006)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
LR Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
